by | Mar 18, 2024 | Publications
Leuk Lymphoma. 2024 Mar 18:1-10. doi: 10.1080/10428194.2024.2322030. Online ahead of print. ABSTRACT Once-weekly carfilzomib at 56 mg/m2 plus immunomodulatory drugs and dexamethasone has shown efficacy and tolerability treating early relapsed/refractory multiple...
by | Mar 18, 2024 | Publications
Intern Med. 2024 Mar 18. doi: 10.2169/internalmedicine.2487-23. Online ahead of print. ABSTRACT Objective Elotuzumab plus lenalidomide and dexamethasone (ELd) was approved in Japan in 2016 for the treatment of relapsed/refractory multiple myeloma (RRMM). This...
by | Mar 17, 2024 | Publications
Hematology. 2024 Dec;29(1):2329029. doi: 10.1080/16078454.2024.2329029. Epub 2024 Mar 15. ABSTRACT OBJECTIVE: To investigate the relationship between 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) related parameters and the...
by | Mar 17, 2024 | Publications
Am J Hematol. 2024 Mar 15. doi: 10.1002/ajh.27288. Online ahead of print. ABSTRACT Thrombosis represents a frequent and potentially severe complication in individuals diagnosed with multiple myeloma (MM). These events can be driven by both the disease as well as the...
by | Mar 17, 2024 | Publications
Clin Lymphoma Myeloma Leuk. 2024 Feb 23:S2152-2650(24)00091-0. doi: 10.1016/j.clml.2024.02.012. Online ahead of print. ABSTRACT BACKGROUND: Melflufen, a first-in-class alkylating peptide-drug conjugate, rapidly enters tumor cells and metabolizes to melphalan. In...
by | Mar 17, 2024 | Publications
Ann Hematol. 2024 Mar 16. doi: 10.1007/s00277-024-05705-z. Online ahead of print. ABSTRACT Elotuzumab-based regimens are sometimes selected for multiple myeloma treatment after daratumumab-based regimens. However, there has been insufficient discussion on the efficacy...